Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs PubMatic Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while PubMatic Inc trades at $18.67 (market cap $850.88M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 14.8× PubMatic Inc's market cap, and PubMatic Inc is more actively traded (997,698 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and PubMatic Inc for 40 Days on average.
| HALO | PUBM | |
|---|---|---|
Market Cap | $12.58B | $850.88M |
Volume | 2,179,278 | 997,698 |
Sector | Health | Technology |
52-Week High | $115.22 | $19.18 |
52-Week Low | $61.63 | $6.28 |
Typical Hold Time | 1 Days | 40 Days |
Enterprise Value | $14.49B | $754.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PubMatic (PUBM) trades at $18.64, up 0.38% on the day, with a bullish technical signal driven by moving averages. The stock has beaten earnings estimates for the last three quarters, though it remains unprofitable with a negative net income margin. Recent news highlights strong Q2 2026 results, AI product adoption, and executive appointments, fueling positive sentiment.
The outlook is cautiously optimistic given analyst consensus and technical momentum, but risks include persistent profitability challenges and competitive pressures. Upside is supported by a $19.89 average price target, though investors should weigh high valuation multiples against earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
